CN110973634A - Nutritional composition for improving hypoevolutism and preparation method thereof - Google Patents
Nutritional composition for improving hypoevolutism and preparation method thereof Download PDFInfo
- Publication number
- CN110973634A CN110973634A CN201911354955.6A CN201911354955A CN110973634A CN 110973634 A CN110973634 A CN 110973634A CN 201911354955 A CN201911354955 A CN 201911354955A CN 110973634 A CN110973634 A CN 110973634A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil microcapsule
- microcapsule powder
- amount
- premix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000843 powder Substances 0.000 claims abstract description 96
- 239000003094 microcapsule Substances 0.000 claims abstract description 68
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 38
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims abstract description 38
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 38
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 23
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 22
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 21
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 21
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 19
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 19
- 235000010216 calcium carbonate Nutrition 0.000 claims abstract description 19
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 19
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 19
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 19
- 235000019172 retinyl palmitate Nutrition 0.000 claims abstract description 19
- 239000011769 retinyl palmitate Substances 0.000 claims abstract description 19
- 229940108325 retinyl palmitate Drugs 0.000 claims abstract description 19
- 229960003080 taurine Drugs 0.000 claims abstract description 19
- 229960000984 tocofersolan Drugs 0.000 claims abstract description 19
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 19
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 19
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 19
- 239000002076 α-tocopherol Substances 0.000 claims abstract description 19
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract description 19
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 19
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 17
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 17
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 17
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 17
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 17
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 17
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 15
- 239000011578 levomefolic acid Substances 0.000 claims abstract description 15
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 15
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 15
- 229940088594 vitamin Drugs 0.000 claims abstract description 15
- 229930003231 vitamin Natural products 0.000 claims abstract description 15
- 235000013343 vitamin Nutrition 0.000 claims abstract description 15
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 14
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 14
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 14
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 14
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims abstract description 13
- 235000007635 levomefolic acid Nutrition 0.000 claims abstract description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 239000010775 animal oil Substances 0.000 claims abstract description 9
- 239000008158 vegetable oil Substances 0.000 claims abstract description 6
- 235000015097 nutrients Nutrition 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 37
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 26
- 238000001291 vacuum drying Methods 0.000 claims description 17
- 235000019498 Walnut oil Nutrition 0.000 claims description 16
- 235000021388 linseed oil Nutrition 0.000 claims description 16
- 239000000944 linseed oil Substances 0.000 claims description 16
- 239000008170 walnut oil Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 14
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 13
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 13
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 13
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 13
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 13
- 229960002477 riboflavin Drugs 0.000 claims description 13
- 235000019192 riboflavin Nutrition 0.000 claims description 13
- 239000002151 riboflavin Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 13
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 13
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 13
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 13
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 206010012559 Developmental delay Diseases 0.000 claims description 9
- 229960003563 calcium carbonate Drugs 0.000 claims description 9
- 229960001708 magnesium carbonate Drugs 0.000 claims description 9
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 241000195493 Cryptophyta Species 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 claims description 3
- 239000010773 plant oil Substances 0.000 claims description 3
- FZDRYCKUVGVDSO-KWWXADPNSA-N (2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid;(2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal Chemical class O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO.C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FZDRYCKUVGVDSO-KWWXADPNSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000003623 enhancer Substances 0.000 description 31
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 26
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 22
- 238000011161 development Methods 0.000 description 21
- 230000018109 developmental process Effects 0.000 description 20
- 239000002994 raw material Substances 0.000 description 18
- 230000012010 growth Effects 0.000 description 16
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 12
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 12
- 210000003754 fetus Anatomy 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 239000002211 L-ascorbic acid Substances 0.000 description 11
- 235000000069 L-ascorbic acid Nutrition 0.000 description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- -1 (6S) -5-methyltetrahydrofolic acid glucosamine salt Chemical class 0.000 description 8
- 210000004958 brain cell Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229930003316 Vitamin D Natural products 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 235000019166 vitamin D Nutrition 0.000 description 7
- 239000011710 vitamin D Substances 0.000 description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 description 7
- 229940046008 vitamin d Drugs 0.000 description 7
- 208000030941 fetal growth restriction Diseases 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 208000032170 Congenital Abnormalities Diseases 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 208000037824 growth disorder Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010070531 Foetal growth restriction Diseases 0.000 description 3
- 206010016880 Folate deficiency Diseases 0.000 description 3
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 206010009260 Cleft lip and palate Diseases 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- 206010070538 Gestational hypertension Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 201000005624 HELLP Syndrome Diseases 0.000 description 2
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000016653 cleft lip/palate Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010060919 Foetal malformation Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 1
- 208000001184 Oligohydramnios Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000036995 brain health Effects 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 230000024764 neural tube development Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to the technical field of nutritional food, and particularly relates to a nutritional composition for improving hypoevolutism, which comprises, by weight, 30-80 parts of plant seed oil microcapsule powder containing α -linolenic acid, 20-100 parts of animal and vegetable oil microcapsule powder containing DHA, 0.001-0.008 part of phosphatidylserine, 0.001-0.005 part of (6S) -5-methyltetrahydrofolate, 1-5 parts of vitamin composition premix, 5-35 parts of calcium carbonate, 0.2-25 parts of magnesium carbonate, 0.5-6 parts of ferrous gluconate, 0.1-3 parts of zinc gluconate, 0.01-0.1 part of retinyl palmitate, 0.01-0.05 part of vitamin D3, 0.1-2 parts of D- α -tocopherol, 0.1-5 parts of taurine and 5-25 parts of soybean protein isolate powder.
Description
Technical Field
The invention belongs to the technical field of nutritional foods, and particularly relates to a nutritional composition for improving hypoevolutism and a preparation method thereof.
Background
Growth retardation (stunting) refers to the phenomenon of slowing down or abnormal sequence in the process of growth and development. The incidence rate is between 6% and 8%. Developmental delays are implicated by a number of factors, such as nutritional deficiencies, systemic disease, familial inheritance, congenital disease or mental factors. Fetal intrauterine growth restriction (FGR) is an obstetrical disorder that seriously compromises fetal life quality and affects childhood and pubertal growth, even leading to a variety of long-term complications, with 80% to 90% of children with developmental delay resulting from intrauterine dysplasia and congenital genetic factors. Some diseases are caused by pathological factors such as chromosome abnormality, bone diseases, metabolic diseases, chronic diseases or chronic malnutrition, endocrine diseases, etc., which can cause growth retardation of children. Pregnant women are the basic source of nutrient substances of fetuses, and the growth and development of the fetuses are influenced by malnutrition of the pregnant women, particularly insufficient supply of protein and energy. In addition, the combination of trace elements essential to human body with amino acids, proteins, etc. can form enzymes and hormones with high biochemical effect and special physiological function, and the deficiency of trace elements and vitamins can affect the growth and development of fetus. For example, zinc deficiency in pregnant women can affect nucleic acid and protein synthesis, decrease the total area of placental villi, affect fetal development, and lead to IUGR and fetal malformation. The enzyme deficiency or insufficient supply of vitamin B6, B12 or folic acid can cause hyperhomocysteinemia, affect fetal placental development, and induce obstetrical complications such as abortion, pregnancy-induced hypertension, IUGR, teratogenesis and early placental stripping. The invention discloses a nutritional composition which has a remarkable effect on both intrauterine growth retardation of a fetus and growth and development retardation of an infant, and provides a new method from the aspects of nutrition absorption and metabolism, so that the nutritional composition has an effect of improving the intrauterine growth retardation of the fetus and the growth and development retardation of the infant.
α -linolenic acid is essential fatty acid of human body, which can be converted into eicosapentaenoic acid and docosahexaenoic acid in human body, α -linolenic acid can increase brain transmission medium (Neurotransmitter), enhance brain activity function, make brain operation more effective and make learning and thinking ability better, α -linolenic acid has most important function for pregnant and lying-in women, which is to control gene expression, optimize genetic gene, transport cell material raw material, control nutrient to enter cells, influence growth and development of brain cells of baby, α -linolenic acid is also brain gold DHA, which can be converted into DHA in baby body, α -linolenic acid is very important for health development of brain, retina, skin and kidney function of baby and baby.
DHA is an important constituent of brain cell membrane, participates in the formation and development of brain cells, plays an important role in the extension of nerve cell axons and the formation of new processes, can maintain the normal physiological activity of nerve cells, and participates in the process of brain thinking and memory formation. May be related to promoting the protein synthesis of nerve cells and promoting the growth of nerve cells. DHA is very closely related to brain health. Increasing DHA content in food, and improving DHA level in brain, so as to enhance learning and memory function, promote brain and nerve health development, and prevent and treat visual deterioration.
Phosphatidylserine forms the cell membrane of nerve cells, activates Protein Kinase C (PKC), and the activated protein kinase C can phosphorylate serine and threonine residues, so that biological information conduction is influenced, and the phosphatidylserine can help repair the cell membrane of the nerve cells of the brain, not only bring nutrients into the cells and discharge waste, but also help the brain cells to be normalized. Phosphatidylserine can help repair the cell membrane, especially for the cranial nerve cell, and not only can bring nutrients into the cell and discharge wastes, but also can help the brain cell to be normalized.
Folic acid is a water-soluble B vitamin essential for maintaining normal life activities of human body, and its main biological function is to provide methyl for methylation reaction in cells and synthesis of deoxyribonucleic acid. Research shows that various birth defects such as neural tube deformity and cleft lip and palate are related to folic acid deficiency in the early pregnancy of women, folic acid is an indispensable nutrient for fetal growth and development, the folic acid deficiency of pregnant women can cause low body weight, cleft lip and palate, heart defect and the like during the birth of the fetus, and the folic acid deficiency in the first 3 months of pregnancy can cause the neural tube development defect of the fetus to cause deformity. In contrast to folic acid, (6S) -5-methyltetrahydrofolate, glucosamine salt is used as a folate with metabolic activity, which is not affected by MTHFR enzyme (methylenetetrahydrofolate reductase) gene polymorphism, can be directly utilized without any metabolic 'finished product' folic acid, and 5-methyltetrahydrofolate is ingested to ensure that Hcy can complete methionine circulation, reduce the content of Hcy in blood, and avoid spontaneous abortion, birth defects and the like caused by Hcy increase in the early pregnancy; relieve the occlusion and angiosclerosis of three-level chorion small blood vessels of placenta and even the thrombosis of the circulatory system of a fetus caused by the increase of Hcy in the middle and late pregnancy, and further cause the adverse effects of oligohydramnios, limited growth and development of the fetus, pregnancy-induced hypertension, premature birth and the like.
The vitamin E can enhance the activity of brain nerve cells of the baby and maintain the normal immune function of the baby, in particular to the function of T lymphocytes. Protecting nervous system, bone marrow muscle, and retina from oxidative damage. Adequate vitamin E is also required for normal development of the human neuromuscular system and maintenance of retinal function. Calcium is a nutrient that maintains heart health, hemostasis, nerve health, muscle contraction, and skin, bone, and tooth health. Zinc is a component of more than 200 enzymes, DNA and RNA in vivo, and is an essential substance for growth and development.
Vitamin D can promote absorption of calcium and phosphorus by small intestinal mucosa, effectively promote growth of osteoclast and new osteocyte of bone, maintain calcium concentration, promote calcium deposition in bone, and harden bone. In addition, vitamin D is also involved in the proliferation and differentiation of various cells and in the regulation of immune function.
The vitamins and minerals are important substances which are indispensable for maintaining the life of the body, and the vitamins participate in a plurality of important life processes of the body and have great health relationship with the human body, because the infants are in the period of vigorous growth and development, the required amount of various vitamins is large, and the vitamins and the minerals should be supplemented. Minerals, also known as inorganic salts, are present in small amounts in the human body, but some are essential for the body tissue and some are involved in maintaining enzymatic and hormonal activities. It is therefore more important to ingest sufficient minerals during the vigorous growth and development period of the infant. The demand of the pregnant women for nutrients is increased because more nutrients are needed for blood circulation of the fetus, development of organs and skeletons of the fetus, growth of placenta, and the like, and the workload of important organs of the mothers is increased. Therefore, during pregnancy, enough multivitamin minerals are needed to be taken, so as to avoid the lack of nutrition in the diet, ensure the body to be in the optimal state and ensure that the blood of the user contains enough nutrients required by the fetus.
Taurine is a nerve inhibitor, and can promote the growth and development of nervous system, and the proliferation and differentiation of nerve cells, and the deficiency of taurine can make the developing cerebellum abnormal, and affect the development of brain and intelligence. In addition, the synthesis of DNA and RNA of brain cells can be promoted, and the content of phosphatidylethanolamine of membranes and the utilization rate of the brain cells to protein are increased, so that the development of the brain cells, particularly the structure and the function of hippocampal cells, is promoted. At present, no comprehensive and targeted nutritional composition exists on the market, and a nutritional preparation for improving the hypoevolutism has single component, is mainly a medicinal preparation for being matched with physical therapy, and the single component is easy to cause poor absorption, so the treatment effect is not ideal.
Disclosure of Invention
The present invention has been made to solve the above problems, and an object of the present invention is to provide a nutritional composition for improving developmental delay and a method for producing a nutritional composition for improving developmental delay, which are aimed at comprehensively improving the nutritional absorption and nutritional metabolism of a mother during embryonic development and a child during growth.
The invention provides a nutritional composition for improving developmental retardation, which has the following specific technical scheme:
the nutritional composition for improving hypoevolutism comprises, by weight, 30-80 parts of plant seed oil microcapsule powder containing α -linolenic acid, 20-100 parts of animal and plant oil microcapsule powder containing DHA, 0.001-0.008 part of phosphatidylserine, 0.001-0.005 part of (6S) -5-methyltetrahydrofolate, 1-5 parts of vitamin composition premix, 5-35 parts of calcium carbonate, 0.2-25 parts of magnesium carbonate, 0.5-6 parts of ferrous gluconate, 0.1-3 parts of zinc gluconate, 0.01-0.1 part of retinyl palmitate, 0.01-0.05 part of vitamin D3, 0.1-2 parts of D- α -tocopherol, 0.1-5 parts of taurine and 5-25 parts of soybean protein isolate powder.
In some embodiments, the α -linolenic acid-containing plant seed oil microcapsule powder comprises linseed oil microcapsule powder and walnut oil microcapsule powder, wherein the weight ratio of the linseed oil microcapsule powder to the walnut oil microcapsule powder is 2:3-5: 1.
In some embodiments, the DHA-containing animal and vegetable oil microcapsule powder is DHA algal oil microcapsule powder, fish oil microcapsule powder, and/or lecithin DHA yolk microcapsule powder.
In some embodiments, the vitamin composition premix is a compound nutrient supplement premix, and each 1000 parts of the compound nutrient supplement premix comprises 10-15 parts of thiamine hydrochloride, 10-15 parts of riboflavin, 10-15 parts of pyridoxine hydrochloride, 1-5 parts of cobalamin, 65-80 parts of nicotinamide, 740-753 parts of L-ascorbic acid, 47-55 parts of D-calcium pantothenate and the balance of starch.
In certain embodiments, the (6S) -5-methyltetrahydrofolate is glucosamine (6S) -5-methyltetrahydrofolate or a combination of calcium (6S) -5-methyltetrahydrofolate and (6S) -5-methyltetrahydrofolate.
In certain embodiments, 30 parts of linseed oil microcapsule powder, 20 parts of walnut oil microcapsule powder, 20 parts of DHA algae oil microcapsule powder, 0.005 part of phosphatidylserine, 0.003 part of (6S) -5-methyltetrahydrofolate glucosamine salt, 3 parts of a compound nutrient supplement premix, 5 parts of calcium carbonate, 2 parts of magnesium carbonate, 1 part of ferrous gluconate, 0.1 part of zinc gluconate, 0.01 part of retinyl palmitate, 0.02 part of vitamin D3, and 0.2 part of D- α -tocopherol.
The invention also provides a preparation method of the nutritional composition for improving hypoevolutism, which is used for preparing the nutritional composition and is characterized by comprising the following steps:
(1) sieving plant seed oil microcapsule powder containing α -linolenic acid, animal and vegetable oil microcapsule powder containing DHA, phosphatidylserine, 6S-5-methyltetrahydrofolate, vitamin composition premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol, taurine and soybean protein isolate powder respectively;
(2) placing the sieved phosphatidylserine, (6S) -5-methyltetrahydrofolate, vitamin composition premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol and taurine into a powder mixer, and uniformly mixing to obtain a mixture A;
(3) placing the sieved plant seed oil microcapsule powder containing α -linolenic acid, animal and plant oil microcapsule powder containing DHA, soybean protein isolate powder and the mixture A in the step (2) into a vacuum drying mixer to be uniformly mixed to obtain the nutritional composition for improving the hypoevolutism;
(4) and (4) preparing the nutrient composition for improving the hypoevolutism in the step (3) into powder, tablets or capsules.
The nutritional composition for improving the hypoevolutism contains abundant nutritional substances such as α -linolenic acid, DHA, (6S) -5-methyltetrahydrofolic acid, multiple vitamin minerals and the like, the nutritional substances can be mutually promoted and absorbed, so that the absorption rate is enhanced, and the nutritional composition can be combined with the traditional physical treatment method, is convenient to eat, has an obvious effect and does not have any obvious side effect.
Drawings
Fig. 1 is a flow chart of a method of preparing a nutritional composition for ameliorating stunted development according to the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings 1 in conjunction with specific embodiments.
Example 1
Weighing 20 parts of linseed oil microcapsule powder, 25 parts of walnut oil microcapsule powder, 100 parts of DHA algae oil microcapsule powder, 0.001 part of phosphatidylserine, (6S) -5-methyltetrahydrofolic acid glucosamine salt, 0.005 part of compound nutrient enhancer premix, 5 parts of calcium carbonate, 0.2 part of magnesium carbonate, 0.5 part of ferrous gluconate, 3 parts of zinc gluconate, 0.1 part of retinyl palmitate, 30.05 parts of vitamin D, 2 parts of D- α -tocopherol, 0.1 part of taurine and 5 parts of soybean protein isolate according to the parts by weight, wherein the compound nutrient enhancer is prepared by processing and uniformly mixing 13 parts of thiamine hydrochloride, 13 parts of riboflavin, 12 parts of pyridoxine hydrochloride, 3 parts of cobalamin, 70 parts of nicotinamide, 745 parts of L-ascorbic acid, 50 parts of D-calcium pantothenate and the balance of starch in a vacuum drying mixer to prepare the nutrient enhancer of tablets, capsules or capsules.
Respectively sieving the weighed materials with a 60-mesh sieve, mixing phosphatidylserine, (6S) -5-methyltetrahydrofolic acid glucosamine salt, a compound nutrient enhancer premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol and taurine for 30min by a powder mixer according to the formula amount to prepare a mixture A, and uniformly mixing linseed oil microcapsule powder, walnut oil microcapsule powder, DHA algal oil microcapsule powder, soybean protein isolate powder and the mixture A for 20-40min by a vacuum drying mixer to prepare the powdery nutrient composition for improving the stunting.
Example 2
The compound nutrient enhancer premix is prepared as follows: every 1000 parts of premix comprises 10 parts of thiamine hydrochloride, 10 parts of riboflavin, 10 parts of pyridoxine hydrochloride, 1 part of cobalamin, 65 parts of nicotinamide, 740 parts of L-ascorbic acid, 47 parts of D-calcium pantothenate and the balance of starch, the raw materials are processed and then are mixed uniformly in a vacuum drying mixer, and the compound nutrient enhancer premix of tablets, powder or capsules is prepared.
The rest of the raw materials for preparing the nutritional composition for improving hypoevolutism in parts by weight and the preparation method are the same as those of example 1.
Example 3
The compound nutrient enhancer premix is prepared as follows: each 1000 parts of premix comprises 15 parts of thiamine hydrochloride, 15 parts of riboflavin, 15 parts of pyridoxine hydrochloride, 5 parts of cobalamin, 80 parts of nicotinamide, 753 parts of L-ascorbic acid, 55 parts of D-calcium pantothenate and the balance of starch, the raw materials are processed and mixed uniformly in a vacuum drying mixer, and the compound nutrient enhancer premix of tablets, powder or capsules is prepared.
The rest of the raw materials for preparing the nutritional composition for improving hypoevolutism in parts by weight and the preparation method are the same as those of example 1.
Example 4
Weighing 50 parts of linseed oil microcapsule powder, 30 parts of walnut oil microcapsule powder, 45 parts of DHA algae oil microcapsule powder, 0.001 part of phosphatidylserine, (6S) -5-methyl tetrahydrofolic acid glucosamine salt, 0.008 part of compound nutrient enhancer premix, 1 part of calcium carbonate, 25 parts of magnesium carbonate, 6 parts of gluconic acid, 0.1 part of zinc gluconate, 0.1 part of retinyl palmitate, 30.01 parts of vitamin D, 0.03 part of D- α -tocopherol, 5 parts of taurine and 25 parts of soybean protein isolate according to the parts by weight, wherein the compound nutrient enhancer is prepared by processing 13 parts of thiamine hydrochloride, 13 parts of riboflavin, 12 parts of pyridoxine hydrochloride, 3 parts of cobalamin, 70 parts of nicotinamide, 745 parts of L-ascorbic acid, 50 parts of D-calcium pantothenate and the balance of starch in each 1000 parts of the premix, and then uniformly mixing the processed raw materials in a vacuum drying mixer to prepare the compound nutrient enhancer of tablets, powder or capsules.
Respectively sieving the weighed materials with a 60-mesh sieve, mixing phosphatidylserine, (6S) -5-methyltetrahydrofolic acid glucosamine salt, a compound nutrient enhancer premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol and taurine for 30min by a powder mixer according to the formula amount to prepare a mixture A, and uniformly mixing linseed oil microcapsule powder, walnut oil microcapsule powder, DHA algal oil microcapsule powder, soybean protein isolate powder and the mixture A for 20-40min by a vacuum drying mixer to prepare the capsule nutritional composition for improving the stunting.
Example 5
The compound nutrient enhancer premix is prepared as follows: every 1000 parts of premix comprises 10 parts of thiamine hydrochloride, 10 parts of riboflavin, 10 parts of pyridoxine hydrochloride, 1 part of cobalamin, 65 parts of nicotinamide, 740 parts of L-ascorbic acid, 47 parts of D-calcium pantothenate and the balance of starch, the raw materials are processed and then are mixed uniformly in a vacuum drying mixer, and the compound nutrient enhancer premix of tablets, powder or capsules is prepared.
The rest of the raw materials for preparing the nutritional composition for improving hypoevolutism in parts by weight and the preparation method are the same as those of example 4.
Example 6
The compound nutrient enhancer premix is prepared as follows: each 1000 parts of premix comprises 15 parts of thiamine hydrochloride, 15 parts of riboflavin, 15 parts of pyridoxine hydrochloride, 5 parts of cobalamin, 80 parts of nicotinamide, 753 parts of L-ascorbic acid, 55 parts of D-calcium pantothenate and the balance of starch, the raw materials are processed and mixed uniformly in a vacuum drying mixer, and the compound nutrient enhancer premix of tablets, powder or capsules is prepared.
The rest of the raw materials for preparing the nutritional composition for improving hypoevolutism in parts by weight and the preparation method are the same as those of example 4.
Example 7
Weighing 30 parts of linseed oil microcapsule powder, 20 parts of walnut oil microcapsule powder, 20 parts of DHA algae oil microcapsule powder, 0.005 part of phosphatidylserine, (6S) -5-methyltetrahydrofolic acid glucosamine salt, 0.003 part of compound nutrient enhancer premix, 3 parts of calcium carbonate, 2 parts of magnesium carbonate, 1 part of gluconic acid, 0.1 part of zinc gluconate, 0.1 part of retinyl palmitate, 30.02 parts of vitamin D, 0.02 part of D- α -tocopherol, 2 parts of taurine and 15 parts of soybean protein isolate according to the parts by weight, wherein the compound nutrient enhancer is prepared by processing 13 parts of thiamine hydrochloride, 13 parts of riboflavin, 12 parts of pyridoxine hydrochloride, 3 parts of cobalamin, 70 parts of nicotinamide, 745 parts of L-ascorbic acid, 50 parts of D-calcium pantothenate and the balance of starch in each 1000 parts of premix, and then uniformly mixing the processed raw materials in a vacuum drying mixer to prepare the compound nutrient enhancer of tablets, powder or capsules.
Respectively sieving the weighed materials with a 60-mesh sieve, mixing phosphatidylserine, (6S) -5-methyltetrahydrofolic acid glucosamine salt, a compound nutrient enhancer premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol and taurine for 30min by a powder mixer according to the formula amount to prepare a mixture A, and uniformly mixing linseed oil microcapsule powder, walnut oil microcapsule powder, DHA algal oil microcapsule powder, soybean protein isolate powder and the mixture A for 20-40min by a vacuum drying mixer to prepare the tablet nutritional composition for improving the stunting.
Example 8
The compound nutrient enhancer premix is prepared as follows: every 1000 parts of premix comprises 10 parts of thiamine hydrochloride, 10 parts of riboflavin, 10 parts of pyridoxine hydrochloride, 1 part of cobalamin, 65 parts of nicotinamide, 740 parts of L-ascorbic acid, 47 parts of D-calcium pantothenate and the balance of starch, the raw materials are processed and then are mixed uniformly in a vacuum drying mixer, and the compound nutrient enhancer premix of tablets, powder or capsules is prepared.
The rest of the raw materials for preparing the nutritional composition for improving hypoevolutism in parts by weight and the preparation method are the same as those of example 7.
Example 9
The compound nutrient enhancer premix is prepared as follows: each 1000 parts of premix comprises 15 parts of thiamine hydrochloride, 15 parts of riboflavin, 15 parts of pyridoxine hydrochloride, 5 parts of cobalamin, 80 parts of nicotinamide, 753 parts of L-ascorbic acid, 55 parts of D-calcium pantothenate and the balance of starch, the raw materials are processed and mixed uniformly in a vacuum drying mixer, and the compound nutrient enhancer premix of tablets, powder or capsules is prepared.
The rest of the raw materials for preparing the nutritional composition for improving hypoevolutism in parts by weight and the preparation method are the same as those of example 7.
Example 10
Weighing 45 parts of linseed oil microcapsule powder, 10 parts of walnut oil microcapsule powder, 20 parts of DHA algae oil microcapsule powder, 0.005 part of phosphatidylserine, (6S) -5-methyltetrahydrofolic acid glucosamine salt, 0.045 part of compound nutrient enhancer premix, 3 parts of calcium carbonate, 2 parts of magnesium carbonate, 1 part of ferrous gluconate, 0.3 part of zinc gluconate, 0.01 part of retinyl palmitate, 30.01 parts of vitamin D, 0.1 part of D- α -tocopherol, 0.2 part of taurine and 15 parts of soybean protein isolate according to parts by weight, wherein the compound nutrient enhancer premix is prepared by 10-14 parts of thiamine hydrochloride, 10-15 parts of riboflavin, 10-15 parts of pyridoxine hydrochloride, 1-5 parts of cobalamin, 65-80 parts of nicotinamide, 740-ascorbic acid and 753 parts of D-calcium pantothenate and the balance of starch in each 1000 parts of premix, and drying the raw materials in a vacuum mixer to prepare a uniform nutrient premix or a compound premix.
The weighed materials are respectively sieved by a 60-mesh sieve, phosphatidylserine, (6S) -5-methyltetrahydrofolic acid glucosamine salt, a compound nutrient enhancer premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol and taurine are mixed for 30min by a powder mixer according to the formula amount to prepare a mixture A, and linseed oil microcapsule powder, walnut oil microcapsule powder, DHA algal oil microcapsule powder, soybean protein isolate and the mixture A are uniformly mixed for 20-40min by a vacuum drying mixer to prepare the powdery nutrient composition for improving the stunting, wherein each bag is 20 g and the dosage is 90 g per day.
48 pregnant women with 8-city intrauterine fetal growth retardation in obstetrical department are selected, wherein the pregnant women are 24-42 years old and 29 years old on average; after 25-35 weeks of pregnancy, 48 pregnant women have 28 vaginal deliveries and 20 cesarean deliveries, and all newborns survive. The weight of the newborn is more than or equal to 2500g and 40 cases, the weight of the newborn is more than or equal to 3000g and 5 cases, wherein the number of delivery weeks of 3 pregnant women is 34-36 weeks, and the weight of the newborn is more than or equal to 2200 g. The effect is remarkable.
Example 11
Weighing 20 parts of linseed oil microcapsule powder, 10 parts of walnut oil microcapsule powder, 45 parts of DHA algae oil microcapsule powder, 0.006 part of phosphatidylserine, (6S) -5-methyl calcium tetrahydrofolate, 2 parts of compound nutrient enhancer premix, 12 parts of calcium carbonate, 2 parts of magnesium carbonate, 3 parts of ferrous gluconate, 0.9 part of zinc gluconate, 0.06 part of retinyl palmitate, 30.02 parts of vitamin D, 0.03 part of D- α -tocopherol, 0.25 part of taurine and 12 parts of soybean protein isolate.
The compound nutrient enhancer premix is prepared by the following steps: every 1000 parts of premix contains 13 parts of thiamine hydrochloride, 13 parts of riboflavin, 12 parts of pyridoxine hydrochloride, 3 parts of cobalamin, 75 parts of nicotinamide, 745 parts of L-ascorbic acid, 50 parts of D-calcium pantothenate and the balance of starch, the raw materials are processed and then are mixed uniformly in a vacuum drying mixer, and the compound nutrient enhancer premix of tablets, powder or capsules is prepared.
The raw materials are respectively sieved by a 60-mesh sieve, phosphatidylserine, (6S) -5-methyltetrahydrofolate calcium, a compound nutrient enhancer premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol and taurine are mixed for 30min by a powder mixer according to the formula amount to prepare a mixture A, and linseed oil microcapsule powder, walnut oil microcapsule powder, DHA algal oil microcapsule powder, soybean protein isolate and the mixture A are uniformly mixed for 20-40min by a vacuum drying mixer to prepare the powdery nutrient composition for improving the hypoevolutism, wherein each bag is 20 g, and the daily dose is 60 g.
298 children of 20 months to 5 years old with short stature and different language and motor ability from the same age are selected, the children are diagnosed as children with hypoevolutism in a children hospital, and after the children are taken for 6 months to 12 months, the physique development index, the language and the motor ability evaluation index of 260 children are close to the level of the same age or have no difference with the level of the same age.
The above description is only for the purpose of illustrating preferred embodiments of the present invention and is not to be construed as limiting the invention, and the present invention is not limited to the above examples, and those skilled in the art should also be able to make various changes, modifications, additions or substitutions within the spirit and scope of the present invention.
Claims (7)
1. The nutritional composition for improving the hypoevolutism is characterized by comprising, by weight, 30-80 parts of plant seed oil microcapsule powder containing α -linolenic acid, 20-100 parts of animal and vegetable oil microcapsule powder containing DHA, 0.001-0.008 part of phosphatidylserine, 0.001-0.005 part of (6S) -5-methyltetrahydrofolate, 1-5 parts of vitamin composition premix, 5-35 parts of calcium carbonate, 0.2-25 parts of magnesium carbonate, 0.5-6 parts of ferrous gluconate, 0.1-3 parts of zinc gluconate, 0.01-0.1 part of retinyl palmitate, 0.01-0.05 part of vitamin D3, 0.1-2 parts of D- α -tocopherol, 0.1-5 parts of taurine and 5-25 parts of soybean protein isolate powder.
2. The nutritional composition for improving developmental delay of claim 1, wherein the plant seed oil microcapsule powder containing α -linolenic acid comprises linseed oil microcapsule powder and walnut oil microcapsule powder, and the weight ratio of the linseed oil microcapsule powder to the walnut oil microcapsule powder is 2:3-5: 1.
3. The nutritional composition for improving developmental delay according to claim 2, wherein the DHA-containing animal and vegetable oil microcapsule powder is DHA algae oil microcapsule powder, fish oil microcapsule powder and/or lecithin DHA yolk microcapsule powder.
4. The nutritional composition for improving developmental delay according to claim 3, wherein the vitamin composition premix is a compound nutrient supplement premix, and each 1000 parts of the compound nutrient supplement premix comprises 10-15 parts of thiamine hydrochloride, 10-15 parts of riboflavin, 10-15 parts of pyridoxine hydrochloride, 1-5 parts of cobalamin, 65-80 parts of nicotinamide, 740-.
5. A nutritional composition for improving developmental delay according to claim 1 wherein the salt of (6S) -5-methyltetrahydrofolate is glucosamine (6S) -5-methyltetrahydrofolate or a mixture of calcium (6S) -5-methyltetrahydrofolate and (6S) -5-methyltetrahydrofolate.
6. The nutritional composition for improving hypoevolutism according to claim 4, wherein the amount of the linseed oil microcapsule powder is 30 parts, the amount of the walnut oil microcapsule powder is 20 parts, the amount of the DHA algal oil microcapsule powder is 20 parts, the amount of the phosphatidylserine is 0.005 part, the amount of the (6S) -5-methyltetrahydrofolate glucosamine salt is 0.003 part, the amount of the compound nutrient premix is 3 parts, the amount of the calcium carbonate is 5 parts, the amount of the magnesium carbonate is 2 parts, the amount of the ferrous gluconate is 1 part, the amount of the zinc gluconate is 0.1 part, the amount of the retinyl palmitate is 0.01 part, the amount of the vitamin D3 is 0.02 part, and the amount of the D- α -tocopherol is 0.2 part.
7. A process for the preparation of a nutritional composition for the amelioration of developmental delay according to any of claims 1-6, comprising the steps of:
(1) sieving plant seed oil microcapsule powder containing α -linolenic acid, animal and vegetable oil microcapsule powder containing DHA, phosphatidylserine, 6S-5-methyltetrahydrofolate, vitamin composition premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol, taurine and soybean protein isolate powder respectively;
(2) placing the sieved phosphatidylserine, (6S) -5-methyltetrahydrofolate, vitamin composition premix, calcium carbonate, magnesium carbonate, ferrous gluconate, zinc gluconate, retinyl palmitate, vitamin D3, D- α -tocopherol and taurine into a powder mixer, and uniformly mixing to obtain a mixture A;
(3) placing the sieved plant seed oil microcapsule powder containing α -linolenic acid, animal and plant oil microcapsule powder containing DHA, soybean protein isolate powder and the mixture A in the step (2) into a vacuum drying mixer to be uniformly mixed to obtain the nutritional composition for improving the hypoevolutism;
(4) and (4) preparing the nutrient composition for improving the hypoevolutism in the step (3) into powder, tablets or capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911354955.6A CN110973634A (en) | 2019-12-25 | 2019-12-25 | Nutritional composition for improving hypoevolutism and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911354955.6A CN110973634A (en) | 2019-12-25 | 2019-12-25 | Nutritional composition for improving hypoevolutism and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110973634A true CN110973634A (en) | 2020-04-10 |
Family
ID=70075288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911354955.6A Pending CN110973634A (en) | 2019-12-25 | 2019-12-25 | Nutritional composition for improving hypoevolutism and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110973634A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060217386A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
| CN102458150A (en) * | 2009-06-02 | 2012-05-16 | 雀巢产品技术援助有限公司 | Nutritional composition for supporting brain development and function of toddlers |
| CN107348480A (en) * | 2017-05-19 | 2017-11-17 | 云南雪域印象生物科技有限公司 | Walnut oil microcapsule albumen powder |
| CN108477622A (en) * | 2018-04-16 | 2018-09-04 | 赵成群 | A kind of infant's global function alimentation composition |
-
2019
- 2019-12-25 CN CN201911354955.6A patent/CN110973634A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060217386A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
| CN102458150A (en) * | 2009-06-02 | 2012-05-16 | 雀巢产品技术援助有限公司 | Nutritional composition for supporting brain development and function of toddlers |
| CN107348480A (en) * | 2017-05-19 | 2017-11-17 | 云南雪域印象生物科技有限公司 | Walnut oil microcapsule albumen powder |
| CN108477622A (en) * | 2018-04-16 | 2018-09-04 | 赵成群 | A kind of infant's global function alimentation composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnaswamy et al. | Importance of folate in human nutrition | |
| US7674490B2 (en) | Food and vitamin preparations containing the natural isomer of reduced folates | |
| MX2007011046A (en) | Nutritional preparations. | |
| CN104382934A (en) | Multivitamin tablet for pregnant women | |
| AU782556B2 (en) | Compositions containing folic acid and reduced folate | |
| CN105962379B (en) | Vitamin B tablets and preparation method thereof | |
| CN106689698B (en) | Milk cow postpartum drenching nutritional supplement and production method thereof | |
| CN107467667B (en) | A kind of compound preparation contained there are two types of unrighted acid and sialic acid | |
| CN101176734A (en) | Nutrients replenisher for replenishing folic acid and vitamin B12 and preparation method thereof | |
| CN105106217A (en) | Nutritional supplement for pregnant women and preparation method thereof | |
| CN101690591A (en) | Yak marrow polypeptide bone growing and height increasing tablets (powder) | |
| CN110973634A (en) | Nutritional composition for improving hypoevolutism and preparation method thereof | |
| US20130064924A1 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| CN107889889A (en) | A kind of formula for the Astaxanthin In Haematococcus Pluvialis milk powder for contributing to recovery of parturient | |
| KR20190113685A (en) | Manufacturing method of companion animal feed utilizing rice with enhanced resistant starch | |
| CN107789444A (en) | A kind of bright hair vitamine soft capsule prescription of pet dog and preparation method thereof | |
| Shonibare et al. | Roles of micronutrients in pregnancy | |
| CN104997020A (en) | Compound lactase composition and application thereof | |
| CN117122061A (en) | Nutritional composition, preparation method, application and medicine thereof | |
| Garg et al. | Nutrition 23 and Nutrients in Pregnancy | |
| CN107773575A (en) | A kind of pet dog is replenished the calcium soft capsule prescription and preparation method thereof | |
| CN107467673B (en) | A kind of compound preparation contained there are three types of unrighted acid and zinc | |
| CN105995136A (en) | Blessed eggs for pregnant women and infants to eat and preparation method thereof | |
| CN115053928A (en) | Milk powder replacing milk for newborn and preparation method thereof | |
| CN117598475A (en) | Total nutrient formula food for special medical use for adults and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |